Evidence map›Paper›PMID 41181707›Full record

ReviewFrontiers in cell and developmental biology2025

Skeleton keys and Trojan horses: a review of therapeutic delivery to the brain.

Rachel E Stoub, Barbara J Bailus

Abstract readReview
In one paragraph

Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rachel E StoubHenry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA, United States.
Barbara J BailusHenry E. Riggs School of Applied Life Sciences, Keck Graduate Institute, Claremont, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The advances in genetic medicine that have occurred in the last few decades have been tempered by the challenges in delivering those medicines to the desired organs and cell types. Nowhere has this delivery challenge been greater than in the brain, due to the blood brain barrier (BBB), often illustrated as an impenetrable castle wall. As the need for neurological therapies grows, an assortment of Trojan horse and skeleton key strategies have been designed to allow passage of therapeutics through the BBB, These range from designer viral vectors, to cell penetrating peptides that can target cell surface receptors, to genetically modifying hematopoietic stem cells, to lipid nanoparticles that pass through the cell membrane. Results: This review will examine the precise method that each delivery vehicle uses to enter and transverse the endothelial layer of the to BBB and arrive in the brain parenchyma. The advantages and challenges of each delivery strategy will be discussed, as will the most recent clinical trials using these technologies. Conclusion: There are several extremely promising delivery vehicles that are able to cross the BBB and deliver genetic therapies to neuronal cells. Several of these delivery vehicles have already been approved for use in patients. As these delivery vehicles become further optimized there is the potential to treat a majority of neurological disease and disorders.

Indexed as

adeno-associated virusblood brain barriercell penetrating peptidefocused ultrasoundhematopoietic stem cellslipid nanoparticlereceptor mediatedtranscytosis

Identifiers

PMID41181707
PMCPMC12575205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.